Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Retained Earnings (2016 - 2026)

Champions Oncology has reported Retained Earnings over the past 16 years, most recently at -$80.4 million for Q1 2026.

  • Quarterly results put Retained Earnings at -$80.4 million for Q1 2026, down 2.94% from a year ago — trailing twelve months through Jan 2026 was -$80.4 million (down 2.94% YoY), and the annual figure for FY2025 was -$79.9 million, up 5.56%.
  • Retained Earnings for Q1 2026 was -$80.4 million at Champions Oncology, roughly flat from -$80.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for CSBR hit a ceiling of -$71.6 million in Q1 2022 and a floor of -$84.6 million in Q2 2024.
  • Median Retained Earnings over the past 5 years was -$79.9 million (2025), compared with a mean of -$78.6 million.
  • Biggest five-year swings in Retained Earnings: dropped 13.39% in 2023 and later rose 7.57% in 2025.
  • Champions Oncology's Retained Earnings stood at -$72.3 million in 2022, then decreased by 13.39% to -$82.0 million in 2023, then decreased by 0.67% to -$82.6 million in 2024, then grew by 2.97% to -$80.1 million in 2025, then decreased by 0.37% to -$80.4 million in 2026.
  • The last three reported values for Retained Earnings were -$80.4 million (Q1 2026), -$80.1 million (Q4 2025), and -$80.4 million (Q3 2025) per Business Quant data.